Comparative Effectiveness of Ustekinumab Versus Vedolizumab in Treating Crohn's Disease After Failure of Anti-TNF Agents: Real-World Evidence

被引：0
|
作者：
Alamer, A. [1 ]
Al Lehaibi, L. [2 ]
Alomar, M. [2 ]
Aldhuwayan, F. [2 ]
Alshouish, S. [2 ]
Al-Ali, A. [3 ]
Almudhry, Z. [4 ]
Almulhim, A. [5 ]
Althagafi, A. [6 ]
Aldosari, S. [7 ]
Alameel, T. [8 ]
机构：
[1] Prince Sattam Bin Abdulaziz Univ, Dept Clin Pharm, Alkharj, Saudi Arabia
[2] Eastern Hlth Cluster Dammam Med Complex, Dept Clin Pharm, Dammam, Saudi Arabia
[3] Eastern Hlth Cluster Dhahran Eye Specialist Hosp, Dept Clin Pharm, Dhahran, Saudi Arabia
[4] Eastern Hlth Cluster Dammam Med Complex, Dept Med, Dammam, Saudi Arabia
[5] King Faisal Univ, Dept Pharm Practice, Coll Clin Pharm, Alhofuf, Saudi Arabia
[6] King Abdulaziz Univ, Dept Pharm Practice, Fac Pharm, Jeddah, Saudi Arabia
[7] Prince Sattam Bin Abdulaziz Univ, Dept Clin Pharm, Coll Pharm, Alkharj, Saudi Arabia
[8] King Fahad Specialist Hosp Dammam, Dept Med, Dammam, Saudi Arabia
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P688
引用
收藏
页码：I1297 / I1297
页数：1
相关论文
共 50 条
  • [21] Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
    Javier P. Gisbert
    María Chaparro
    Drugs, 2023, 83 : 1179 - 1205
  • [22] Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's Disease
    Gisbert, Javier P.
    Chaparro, Maria
    DRUGS, 2023, 83 (13) : 1179 - 1205
  • [23] COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB AND USTEKINUMAB IN ANTI-TNF REFRACTORY CROHN'S DISEASE: MULTI-CENTRE RETROSPECTIVE COHORT STUDY
    Townsend, Tristan
    Razanskaite, Violeta
    Michail, Stephanie
    Morgan, James
    Davies, Michael
    Storey, Daniel
    Watters, Christopher
    Penman, Douglas
    Swaminathan, Mira
    Reilly, Ian
    Flanagan, Paul
    Subramanian, Sreedhar
    GUT, 2021, 70 : A127 - A127
  • [24] Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
    Cassandra Rayer
    Maria Nachury
    Arnaud Bourreille
    Xavier Roblin
    Laurent Peyrin-Biroulet
    Stephanie Viennot
    Mathurin Flamant
    David Laharie
    Bénédicte Caron
    Marie Dewitte
    Laurent Siproudhis
    Mathurin Fumery
    Guillaume Bouguen
    BMC Gastroenterology, 22
  • [25] Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study
    Cassandra, Rayer
    Nachury, Maria
    Arnaud, Bourreille
    Xavier, Roblin
    Laurent, Peyrin-Biroulet
    Stephanie, Viennot
    Mathurin, Flamant
    David, Laharie
    Benedicte, Caron
    Marie, Dewitte
    Laurent, Siproudhis
    Mathurin, Fumery
    Guillaume, Bouguen
    BMC GASTROENTEROLOGY, 2022, 22 (01)
  • [26] The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab
    Kassouri, Liza
    Amiot, Aurelien
    Kirchgesner, Julien
    Treton, Xavier
    Allez, Mathieu
    Bouhnik, Yoram
    Beaugerie, Laurent
    Carbonnel, Franck
    Meyer, Antoine
    DIGESTIVE AND LIVER DISEASE, 2020, 52 (10) : 1148 - 1155
  • [27] Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF,Vedolizumab or Ustekinumab: A Real-World Multicentre European Study
    Yanai, Henit
    Kagramanova, Anna
    Knyazev, Oleg
    Sabino, Joao
    Haenen, Shana
    Mantzaris, Gerassimos J.
    Mountaki, Katerina
    Armuzzi, Alessandro
    Pugliese, Daniela
    Furfaro, Federica
    Fiorino, Gionata
    Drobne, David
    Kurent, Tina
    Yassin, Sharif
    Maharshak, Nitsan
    Castiglione, Fabiana
    de Sire, Roberto
    Nardone, Olga Maria
    Farkas, Klaudia
    Molnar, Tamas
    Krznaric, Zeljko
    Brinar, Marko
    Chashkova, Elena
    Margolin, Moran Livne
    Kopylov, Uri
    Bezzio, Cristina
    Shitrit, Ariella Bar-Gil
    Lukas, Milan
    Chaparro, Maria
    Truyens, Marie
    Nancey, Stephane
    Lobaton, Triana
    Gisbert, Javier P.
    Saibeni, Simone
    Bacsur, Peter
    Bossuyt, Peter
    Schulberg, Julien
    Hoentjen, Frank
    Vigano, Chiara
    Palermo, Andrea
    Torres, Joana
    Reves, Joana
    Karmiris, Konstantinos
    Velegraki, Magdalini
    Savarino, Edoardo
    Markopoulos, Panagiotis
    Tsironi, Eftychia
    Ellul, Pierre
    Suarez, Cristina Calvino
    Weisshof, Roni
    JOURNAL OF CROHNS & COLITIS, 2022, 16 (12): : 1882 - 1892
  • [28] Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
    Cassandra Rayer
    Maria Nachury
    Arnaud Bourreille
    Xavier Roblin
    Laurent Peyrin-Biroulet
    Stephanie Viennot
    Mathurin Flamant
    David Laharie
    Bénédicte Caron
    Marie Dewitte
    Laurent Siproudhis
    Mathurin Fumery
    Guillaume Bouguen
    BMC Gastroenterology, 23
  • [29] Early real-world effectiveness of ustekinumab for Crohn's disease
    Harris, Richard James
    McDonnell, Martin
    Young, David
    Bettey, Marion
    Downey, Louise
    Pigott, Lucinda
    Felwick, Richard
    Gwiggner, Markus
    Cummings, J. R. Fraser
    FRONTLINE GASTROENTEROLOGY, 2020, 11 (02) : 111 - 116
  • [30] Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn's disease patients: results from the EVOLVE study
    Bressler, B.
    Mantzaris, G.
    Silverberg, M.
    Zezos, P.
    Stein, D.
    Colby, C.
    Lissoos, T.
    Lopez, C.
    Natsios, A.
    Radulescu, G.
    Patel, H.
    Demuth, D.
    Yarur, A.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S427 - S428
12345